INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
Recruiting · NCT03838042 · Registry updated 2024-02-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | Neoplasms by Site, central nervous system cancer, central nervous system neoplasm, neoplasm, nervous system disorder | Recruiting | Phase 1 / Phase 2 | 2024-02-07 | NCT03838042 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| German Cancer Research Center | 47 |
| University Hospital Heidelberg | 109 |
14 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Augsburg University Hospital | Augsburg | Germany | 1 |
| Charité University Medicine Berlin | Berlin | Germany | 1 |
| Children's Hospital at Westmead | Westmead | Australia | 9 |
| Children's Hospital Zurich | Zurich | Switzerland | 1 |
| Essen University Hospital | Essen | Germany | 2 |
| Hannover Medical School | Hanover | Germany | 11 |
| Hopp Children's Cancer Center Heidelberg (KiTZ) | Heidelberg | Germany | 1 |
| Institut Curie | Paris | France | 81 |
| Karolinska Institute | Stockholm | Sweden | 6 |
| Perth Children's Hospital | Nedlands | Australia | 20 |
| Prinses Máxima Centrum | Utrecht | Netherlands | 1 |
| Royal Children's Hospital | Parkville | Australia | 40 |
| St. Anna Children's Hospital | Vienna | Austria | 2 |
| Sydney Children's Hospital | Randwick | Australia | 43 |